1. Home
  2. APRE vs AEHL Comparison

APRE vs AEHL Comparison

Compare APRE & AEHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • AEHL
  • Stock Information
  • Founded
  • APRE 2006
  • AEHL 1993
  • Country
  • APRE United States
  • AEHL China
  • Employees
  • APRE N/A
  • AEHL N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • AEHL Building Materials
  • Sector
  • APRE Health Care
  • AEHL Industrials
  • Exchange
  • APRE Nasdaq
  • AEHL Nasdaq
  • Market Cap
  • APRE 9.7M
  • AEHL 7.8M
  • IPO Year
  • APRE 2019
  • AEHL 2007
  • Fundamental
  • Price
  • APRE $1.75
  • AEHL $2.20
  • Analyst Decision
  • APRE Strong Buy
  • AEHL
  • Analyst Count
  • APRE 2
  • AEHL 0
  • Target Price
  • APRE $15.50
  • AEHL N/A
  • AVG Volume (30 Days)
  • APRE 35.9K
  • AEHL 197.6K
  • Earning Date
  • APRE 05-14-2025
  • AEHL 05-01-2025
  • Dividend Yield
  • APRE N/A
  • AEHL N/A
  • EPS Growth
  • APRE N/A
  • AEHL N/A
  • EPS
  • APRE N/A
  • AEHL N/A
  • Revenue
  • APRE $1,284,475.00
  • AEHL $98,773,000.00
  • Revenue This Year
  • APRE N/A
  • AEHL N/A
  • Revenue Next Year
  • APRE N/A
  • AEHL N/A
  • P/E Ratio
  • APRE N/A
  • AEHL N/A
  • Revenue Growth
  • APRE 33.27
  • AEHL 36.99
  • 52 Week Low
  • APRE $1.41
  • AEHL $1.79
  • 52 Week High
  • APRE $5.01
  • AEHL $256.40
  • Technical
  • Relative Strength Index (RSI)
  • APRE 49.51
  • AEHL 43.59
  • Support Level
  • APRE $1.60
  • AEHL $1.79
  • Resistance Level
  • APRE $2.00
  • AEHL $2.41
  • Average True Range (ATR)
  • APRE 0.16
  • AEHL 0.27
  • MACD
  • APRE 0.02
  • AEHL 0.01
  • Stochastic Oscillator
  • APRE 37.50
  • AEHL 41.85

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About AEHL Antelope Enterprise Holdings Limited

Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.

Share on Social Networks: